Opinion|Videos|July 10, 2024

Discontinuation or Continuation of IO Therapy – IO/IO vs. IO/TKI Regimens

Author(s)Matthew T. Campbell, MD, MS, Rana R. McKay, MD

Dr. Campbell evaluates the efficacy and safety results from the 55-month analysis of the CheckMate-9ER trial, and explores the considerations for discontinuing or continuing immunotherapy (IO) in IO/IO versus IO/TKI combination regimens.

Episodes in this series

2 KOLs are featured in this program.

EP. 1 Current treatment options for ccRCC based on patient and disease factors

2 KOLs are featured in this program.

EP. 2 CheckMate-214: Long-term follow-up data

2 KOLs are featured in this program.

EP. 3 Review of CheckMate-214: Long-term follow-up in favorable risk subgroup

2 KOLs are featured in this program.

EP. 4 Review of CLEAR and CheckMate-9ER: Four-Year and 55 Month Follow-Up Data

2 KOLs are featured in this program.

EP. 5 Review of KEYNOTE-426: Five-year Follow-up Data

2 KOLs are featured in this program.

EP. 6 Discontinuation or Continuation of IO Therapy – IO/IO vs. IO/TKI Regimens

2 KOLs are featured in this program.

EP. 7 Treatment-free survival in IO/TKI

2 KOLs are featured in this program.

EP. 8 Biomarkers: Impact on Treatment Choices and Future Expectations

2 KOLs are featured in this program.

EP. 9 Management of Adverse Events – IO/IO and IO/TKI

2 KOLs are featured in this program.

EP. 10 New formulations for current therapies – SC vs. IV

2 KOLs are featured in this program.

EP. 11 Novel Agents/Combinations for aRCC

Dr Campbell: Please briefly review key efficacy and safety data from the CheckMate-9ER trial 55 month analysis (Bourlon MT, et al. 2024 ASCO Annual Meeting. Abstract 362).

What are the clinical implications of these data for treatment-naïve patients with advanced RCC?
In responders, how important is the durability of the response (OS and PFS) for both the intermediate/poor and favorable-risk groups?

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Considering the Role of Tivozanib After Prior ICI-Based Therapy in RCC

October 16th, 2026

Considering the Role of Tivozanib After Prior ICI-Based Therapy in RCC

Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.

How Disease Burden Shapes First-Line RCC Treatment Selection

October 13th, 2026

How Disease Burden Shapes First-Line RCC Treatment Selection

Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.

Heng on Managing Toxicity and Sequencing With Belzutifan/Lenvatinib in RCC

October 8th, 2026

Heng on Managing Toxicity and Sequencing With Belzutifan/Lenvatinib in RCC

Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

2026 AACR Report Highlights Advances and New Directions in Cancer Treatment

Amivantamab vs. Emerging EGFR Bispecifics in HNSCC

ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types

Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer

Dr Beck on the Practical Realities of Subcutaneous Oncology Drug Delivery